Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Videx (Didanosine, ddI)

The Basics | News | Research

See also: Drug Interactions | Medication Side Effects

Show Archived (Historical) Articles

Brand Name:	Videx EC
Generic Name:	Didanosine, ddI
Adult Single Dose:	Patients weighing at least 133 lbs (60 kg): one 400-mg capsule (once a day) Patients weighing less than 133 lbs (60 kg): one 250-mg capsule (once a day)
Food & Liquid Restrictions:	Take on an empty stomach, at least 30 minutes before or two hours after eating or drinking, except water. Do not take Videx EC with food.
Drug Class:	NRTI

The Basics

An Overview of Videx (Didanosine, ddI) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Videx EC (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Didanosine (Videx, ddI) (November 16, 2008)
To read PDF, click here
From AIDS InfoNet
Patient Information About Videx (Didanosine, ddI) (PDF) (September 2008)
From Bristol-Myers Squibb Company
Videx EC (Didanosine, ddI EC) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
ddI (Videx, didanosine) (August 15, 2006)
From AIDS Treatment Data Network

News

Important Changes to Videx (Didanosine) Labeling (June 19, 2009)
From U.S. Food and Drug Administration
Videx EC Labeling Changes With Pediatric Dosing Information Added (September 30, 2008)
From U.S. Food and Drug Administration

Research

Emtriva + Reyataz + Videx Not as Effective as Combivir + Sustiva in First-Line Therapy, Study Finds (May 28, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here
From D:A:D Steering Committee
HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.